Yiming Cheng, PhD
About Yiming Cheng, PhD
Yiming Cheng, PhD, is a Senior Research Investigator at Bristol-Myers Squibb, specializing in clinical pharmacology for hematological drug development. He has a strong background in pharmacokinetics and pharmacometrics, with previous experience at Novartis and Sanofi.
Current Role at Bristol-Myers Squibb
Yiming Cheng, PhD, serves as a Senior Research Investigator at Bristol-Myers Squibb in the United States. He began this role in February 2020. In his position, he focuses on clinical pharmacology efforts specifically for hematological drug development. His work involves leveraging his expertise in pharmacokinetics and pharmacometrics to contribute to the development of new therapies in hematology.
Previous Experience at Novartis and Sanofi
Before joining Bristol-Myers Squibb, Yiming Cheng gained valuable experience through internships at Novartis and Sanofi. In 2019, he worked as a Pharmacokinetic (PK) - Oncology Intern at Novartis in East Hanover, New Jersey, for two months. Prior to that, he completed a three-month internship in 2018 at Sanofi in Bridgewater, New Jersey, where he was involved in the Pharmacokinetics, Dynamics, and Metabolism (PKDM) department. These roles provided him with hands-on experience in pharmacokinetics and metabolism within the fields of oncology and broader medical research.
Educational Background
Yiming Cheng holds a Doctor of Philosophy (PhD) in Biomedical Engineering from both Rutgers University and the New Jersey Institute of Technology, where he studied from 2015 to 2019. Additionally, he earned a Master of Science (MS) in Biomedical/Medical Engineering from the New Jersey Institute of Technology, which he completed between 2012 and 2014. His undergraduate studies were completed at Tongji University, where he obtained a Bachelor of Science (BS) in Biotechnology from 2008 to 2012.
Expertise in Pharmacokinetics and Pharmacodynamics
Dr. Cheng is recognized for his strong background in clinical pharmacology, with a particular focus on pharmacokinetics and pharmacometrics. His expertise in these areas is critical to his role in developing new hematological therapies at Bristol-Myers Squibb. His proficiency in analyzing and modeling drug kinetics and dynamics contributes significantly to the advancement of treatments in hematology.